Phase II Randomized Study of Atezolizumab Plus Chemoradiotherapy Versus Chemoradiotherapy Alone in Limited Disease Small-Cell Lung Cancer

The primary objective of this randomized phase II study is to evaluate whether **atezolizumab** improves overall survival in patients with limited disease small-cell lung cancer (LD SCLC) who have completed concurrent chemoradiotherapy. This is clinically relevant as improving survival rates in LD SCLC remains a significant challenge, and atezolizumab, an immune checkpoint inhibitor, may offer a novel therapeutic approach to enhance patient outcomes.

The clinical trial involves a total of **20 participants** diagnosed with **limited disease small-cell lung cancer**. The study population includes both male and female subjects, aged 18 years and older, who have provided written informed consent. Participants have a histologically or cytologically confirmed diagnosis of small-cell lung cancer, classified as Stage I-III according to TNM v8, and are ineligible for surgery, provided all lesions can be included in a tolerable radiotherapy field. The trial population was selected based on specific inclusion criteria, including an ECOG performance status of 0-2 and adequate kidney, liver, and bone marrow function. Additionally, participants must have measurable disease according to RECIST 1.1 if enrolled before the commencement of chemoradiotherapy. Pulmonary function requirements include FEV1 >1 L or >30% of the predicted value and DLCO >30% of the predicted value, with allowances for reduced lung function due to tumor obstruction, provided a radiotherapist deems the patient eligible for thoracic radiotherapy. The trial does not include a vulnerable population, and no specific lifestyle considerations such as diet or physical activity are highlighted in the selection criteria.

The clinical trial is designed as a **randomized**, phase II study to evaluate the efficacy of **atezolizumab** following concurrent chemoradiotherapy compared to chemoradiotherapy alone in patients with limited disease small-cell lung cancer. The primary objective is to assess whether atezolizumab improves overall survival in patients who have completed chemoradiotherapy. Secondary endpoints include best response rates, progression-free survival, toxicity, and health-related quality of life. The trial is structured as a **double-blind**, controlled study to ensure unbiased results.

Participants will be involved in the study for a maximum treatment period of 52 weeks. The trial is expected to conclude by December 31, 2042, with recruitment having commenced on July 31, 2018. The study will include several key visits: an initial screening visit to confirm eligibility based on criteria such as age, performance status, and adequate organ function; regular follow-up visits to monitor treatment response and adverse events; and an end-of-study visit to assess final outcomes and collect data on overall survival and secondary endpoints.

Inclusion criteria require participants to be 18 years or older, provide written informed consent, and have histologically or cytologically confirmed small-cell lung cancer at stage I-III, ineligible for surgery but suitable for radiotherapy. Exclusion criteria are not specified in the provided data. Participants may be withdrawn from the study if they experience unacceptable toxicity, withdraw consent, or if the investigator deems it necessary for safety reasons. The study drug, Tecentriq, is administered as a concentrate for solution for infusion via intravenous infusion, with a maximum daily dose of 1200 mg and a total dose not exceeding 20400 mg over the treatment period.

The clinical trial involves the administration of **Tecentriq** (atezolizumab), a **concentrate for solution for infusion**. Tecentriq is provided in a pharmaceutical form suitable for intravenous infusion. The active substance, **atezolizumab**, is a protein-based therapeutic agent classified under the ATC code L01FF05. The maximum daily dose of Tecentriq is 1200 mg, with a total maximum dose of 20400 mg over the course of the treatment. The treatment period is set to a maximum of 52 weeks. The administration of Tecentriq is conducted via intravenous infusion, ensuring precise delivery of the medication directly into the bloodstream. The product is manufactured by Roche Registration GmbH and is not formulated for pediatric use.

In this randomized phase II study, Tecentriq is being evaluated for its efficacy in improving overall survival in patients with limited disease small-cell lung cancer (LD SCLC) who have completed concurrent chemoradiotherapy. The trial compares the outcomes of patients receiving atezolizumab following chemoradiotherapy against those receiving chemoradiotherapy alone. The study does not include any additional non-experimental treatments such as placebo or comparator treatments. Participant compliance with the dosing schedule is monitored throughout the trial to ensure adherence to the treatment protocol.

Efficacy in this clinical trial will be assessed primarily through the measurement of **overall survival** in patients with limited disease small-cell lung cancer (LD SCLC) who have completed chemoradiotherapy. This primary endpoint will provide a direct evaluation of the potential survival benefit of adding atezolizumab to the treatment regimen. Secondary endpoints include best response rates, progression-free survival, toxicity, and health-related quality of life. These parameters will offer additional insights into the treatment's impact on disease progression, patient safety, and overall well-being.

The trial is designed as a randomized phase II study, comparing the efficacy of atezolizumab following concurrent chemoradiotherapy against chemoradiotherapy alone. The study will involve a sample size of 215 patients, with eligibility criteria including age ≥ 18 years, confirmed diagnosis of small-cell lung cancer, and adequate organ function, among others. The trial is expected to run until December 31, 2042, with recruitment having started on July 31, 2018. The maximum treatment period for participants receiving atezolizumab is set at 52 weeks.